For the quarter ending 2025-06-30.
| Income Statement | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenues | 0 | - | 10 | 4 |
| Selling, general and administrative expense | - | - | 1,237 | 1,625 |
| Revenues-Clinical Trial Supply | 0 | - | - | - |
| Research and development | 68 | 822 | 950 | 2,023 |
| General and administrative | 1,249 | 4,214 | - | - |
| Total operating expenses | 1,317 | 5,036 | 2,187 | 3,648 |
| Operating loss | -1,317 | -5,036 | -2,177 | -3,644 |
| Other income, net | 2 | 10 | - | - |
| Amount before accretion (amortization) of purchase discount (premium) of interest income expense on nonoperating securities | - | - | 8 | -28 |
| Interest income | 2 | 6 | - | - |
| Foreign exchange losses | -3 | -8 | 2 | 3 |
| Gain on deconsolidation of subsidiary | 0 | 4,947 | - | - |
| Total other income (expense), net | 1 | 4,955 | 10 | -25 |
| Loss before taxes | -1,316 | -81 | -2,167 | -3,669 |
| Income tax benefit | 2 | - | -210 | -412 |
| Net loss | -1,318 | -81 | -1,957 | -3,257 |
| Dividend on convertible exchangeable preferred shares | 20 | - | - | - |
| Net income (loss) available to common stockholders, diluted, total | - | - | -1,957 | -3,257 |
| Net loss applicable to common shareholders | -1,338 | -81 | - | - |
| Net loss per share, basic | -0.98 | 0 | -0.18 | -0.72 |
| Net loss per share, diluted | -0.98 | 0 | - | -0.72 |
Cyclacel Pharmaceuticals, Inc. (CYCC)
Cyclacel Pharmaceuticals, Inc. (CYCC)